Navigation Links
Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
Date:10/18/2009

LA JOLLA, Calif., Oct. 18 /PRNewswire/ -- Fate Therapeutics, Inc. announced today the generation of human induced pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D., under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200 fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, reprogrammed cells that can be produced without genetic modification at commercial scale quantity, quality and consistency and continues to bolster the leadership position of Fate Therapeutics in industrialized iPSC technology. The Company is developing minimally invasive techniques for reprogramming and differentiation and has exclusively in-licensed from TSRI and the Whitehead Institute for Biomedical Research an intellectual property portfolio related to iPSC technology dating back to November 2003.

"While recent studies have reported improved methods of reprogramming, those techniques have relied on further genetic manipulation or have not otherwise addressed a fundamental reprogramming challenge - that iPSC generation is still a very slow and inefficient process and results in a heterogeneous population of cells," said Paul Grayson, president and CEO of Fate Therapeutics. "Once again, Dr. Ding and his team are the first group to clear yet another major hurdle required for the widespread commercial use of iPSCs for drug discovery and patient therapies."

The findings of Dr. Ding and his colleagues are published today in the Advanced Online edition of the s
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
4. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
5. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
6. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
7. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
8. Reportlinker Adds Stem Cell Therapeutics Markets Report
9. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
10. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
11. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Cayenne Medical, ... specializing in the soft tissue reconstruction segment, announced ... System for surgeries involving the shoulder and extremities. ... a novel, inserter-controlled deployment method. The unique delivery ... deployment, anchor pull-out, or anchor displacement (also commonly ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Senior ... institutions and professional associations, addressed the challenges of “Reducing ... Medical Device Industries” through strategic sourcing. Describing the partnership ... with the Supply Chain Management Institute ( SCMI) ... event on June 24 at the Kroc Institute of ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
Breaking Biology Technology:Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... by the National Nanotechnology Initiative (NNI) and the Oregon ... landscape of regional, state, and local (RSL) nanotechnology initiatives. ... visits on April 30 Where: Portland, Oregon ... Street, Portland, OR Who: Leaders of regional, ...
... PML Consortium, an association of pharmaceutical and biotechnology companies, ... from BioFortis to share and manage data relating to ... adverse event. Progressive multifocal leukoencephalopathy (PML) is ... immunocompromised patients. PML has been identified as a known ...
... about the disease and its overall occurrence and progression ... market. This is being exacerbated by the limited availability ... need for innovative and enhanced therapeutic and diagnostic tools ... treatment options. New analysis from Frost & ...
Cached Biology Technology:Registration now open: 2012 Regional, State, and Local Initiatives in Nanotechnology 2Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 2European Multiple Sclerosis Market in Dire Need of Increased Disease Awareness and Treatment Options, Cautions Frost & Sullivan 3
(Date:7/10/2014)... June 30, 2014  Aware, Inc. (NASDAQ: ... services, previously announced on June 26, 2014 that its ... of $1.75 per share, or approximately $40 million in ... 10, 2014 and a payment date of July 24, ... it had set an ex-dividend date for this special ...
(Date:7/10/2014)... July 2, 2014 It is a great ... the appointment of the world-renowned Thoracic and Cardiovascular surgeon, ... Dr. Ginsburg, with over 34 years of ... Hospital and Good Samaritan Regional Medical Center. Dr. Ginsburg ... late 1980,s and is considered an expert in the ...
(Date:7/10/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ) has ... Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, ... to their offering http://photos.prnewswire.com/prnh/20130307/600769 ... Sensing Market to Grow Exponentially. Touch-less sensing applications ... companies were unable to leverage this technology due ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... new study published as the cover article for the April ... ) promises to give physicians new ways to reduce deadly ... cord. In the report, scientists from Columbia University, NY, detail ... cells, called astrocytes, use to handle invading viruses and to ...
... Novocell, Inc., a stem cell engineering company, today announced ... covering human definitive endoderm cells, an essential cell for ... developing for use as a cell therapy for diabetes, ... as lungs, intestine, liver, thymus and thyroid. ...
... CORVALLIS, Ore. Studies done with laboratory rats suggest that ... effect in lowering triglycerides, which along with cholesterol levels and ... cardiovascular disease. In the lab animals, supplements of lipoic ... effect were the same in humans which is not ...
Cached Biology News:West Nile virus studies show how star-shaped brain cells cope with infection 2New approach discovered to lowering triglycerides 2New approach discovered to lowering triglycerides 3
... include: Microarray hybridization chamber assembly (1 ... clamp, thumbscrew) Microarray chamber user guide ... intended to be cleaned and reused. The ... Catalog Oligo Microarray kits and all custom ...
... With the macro- and ... Hoagland and Arnon (1938). ... to contain 1.6 grams ... liter of medium. Physical ...
... separation and fractionation of nucleic-acid ... nuclei from cytosolic proteins A ... greatly facilitating study of low-abundance ... acid binding proteins (e.g., transcription ...
... modifications of Eagle's medium have ... formulation. The most widely used ... DME is a modification of ... that contains a higher concentration ...
Biology Products: